<DOC>
	<DOCNO>NCT00943449</DOCNO>
	<brief_summary>The purpose study determine whether 4SC-201 alone combination Sorafenib effective safe treatment hepatocellular carcinoma patient refractory Sorafenib monotherapy .</brief_summary>
	<brief_title>4SC-201 ( Resminostat ) Sorafenib Advanced Hepatocellular Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Main Advanced stage hepatocellular carcinoma Patients exhibit progressive disease Sorafenib treatment ChildPugh class A B . Only patient ChildPugh index class B 7 include ECOG performance status 0 , 1 2 Precedent firstline treatment Sorafenib minimum continuous dose 400 mg per day least 8 week Main Previous concurrent cancer distinct primary site histology HCC , EXCEPT cervical carcinoma situ , treat basal cell carcinoma , superficial bladder tumor ( Ta , Tis T1 ) cancer curatively treat &gt; 3 year prior entry permit Renal failure require hemo peritoneal dialysis Known central nervous system ( CNS ) tumor include symptomatic brain metastasis ChildPugh index class B combination slight ascites hepatic encephalopathy &gt; Grade I Pregnant breastfeed woman Sorafenib intolerance Major surgery within last 4 week</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Hepatocellular Carcinoma</keyword>
	<keyword>Sorafenib</keyword>
	<keyword>HDAC</keyword>
	<keyword>4SC-201</keyword>
	<keyword>Phase II</keyword>
	<keyword>Resminostat</keyword>
</DOC>